Human variability in polymorphic CYP2D6 metabolism: Is the kinetic default uncertainty factor adequate?

Food and Chemical Toxicology

Volumn 40, Issue 11, 2002, Pages 1633-1656

  Dorne, J L C M ^a   Walton, K ^a   Slob, W ^b   Renwick, A G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

CYP2D6; Human variability; Pharmacokinetics; Risk assessment; Sensitive subgroups; Uncertainty factors

Indexed keywords

AMITRIPTYLINE; CODEINE; CYTOCHROME P450 2D6; DESIPRAMINE; DIHYDROCODEINE; ENCAINIDE; HYDROCODONE; IMIPRAMINE; METOPROLOL; MEXILETINE; NORTRIPTYLINE; PROPAFENONE; PROPRANOLOL; PROPRANOLOL DERIVATIVE; SPARTEINE; TOLTERODINE; VENLAFAXINE;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG CLEARANCE; DRUG METABOLISM; ENZYME KINETICS; ENZYME METABOLISM; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; ETHNOLOGY; FEMALE; GENETIC VARIABILITY; HUMAN; INFANT; LONG TERM EXPOSURE; MALE; NEWBORN; PHENOTYPE; POPULATION; RISK ASSESSMENT; STATISTICAL ANALYSIS;

ADULT; AGED; AGING; BENZHYDRYL COMPOUNDS; CRESOLS; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; DESIPRAMINE; ENCAINIDE; ETHNIC GROUPS; HUMANS; HYDROXYLATION; INFANT; INFANT, NEWBORN; KIDNEY DISEASES; KINETICS; LIVER DISEASES; METABOLIC CLEARANCE RATE; METOPROLOL; PHENYLPROPANOLAMINE; POLYMORPHISM, GENETIC; PROPAFENONE; SUBSTRATE SPECIFICITY; VARIATION (GENETICS);

EID: 0036046179     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(02)00117-5     Document Type: Article

References (152)

1. Imipramine and desipramine disposition in the elderly
2. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans
3. Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations
4. Estimating steady state desipramine levels in noninstitutionalized elderly patients using single dose disposition parameters
5. Food increases the bioavailability of propafenone
6. Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man
7. Pharmacokinetics of two beta blocking drugs: Detection of a pharmacogenetic abnormality
8. Encainide disposition in patients with chronic cirrhosis
9. Encainide disposition in patients with renal failure
10. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction
11. Metabolism of metoprolol-(3-H) in man, the dog and the rat
12. Relationships between debrisoquine hydroxylation and propafenone pharmacokinetics
13. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: Molecular base for interaction potential and variable disposition of active metabolites
14. Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides
15. Quantification of metoprolol beta-2-adrenoceptor antagonism in asthmatic patients by pharmacokinetic-pharmacodynamic modelling
16. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes
17. Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine
18. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man
19. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes
20. Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype
21. First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype
22. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine
23. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine
24. Pharmacokinetics and pharmacodynamics of tolterodine in man: A new drug for the treatment of urinary bladder overactivity
25. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine
26. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity
27. Fluoxetine inhibits the metabolism of tolterodine: Pharmacokinetic implications and proposed clinical relevance
28. CYP2D6*17 in African Americans decreases the metabolism of tolterodine but not the effective exposure
29. Propafenone disposition in renal insufficiency and renal failure
30. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects
31. CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN chinese subjects
32. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers
33. Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers
34. The role of S-mephenytoin 4′-hydroxylase in imipramine metabolism by human liver microsomes: A two-enzyme kinetic analysis of N-demethylation and 2- hydroxylation
35. Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers
36. Absence of effect of stimulants on the pharmacokinetics of desipramine in children
37. Propafenone disposition kinetics in cardiac arrhythmia
38. Similar pharmacokinetics of desipramine in young and aged patients
39. Genetic contribution to interethnic variations in drug oxidation
40. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes
41. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes
42. Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: A comparison with conventional formulations of metoprolol and atenolol
43. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygense catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)
44. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers
45. Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers
46. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6
47. Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone
48. Uncertainty factors for chemical risk assessment: Human variability in the pharmacokinetics of CYP1A2 probe substrates
49. Human variability in glucuronidation in relation to uncertainty factors for risk assessment
50. Influence of the defective metabolism of sparteine on its pharmacokinetics
51. The genetic polymorphism of sparteine metabolism
52. Dihydrocodeine: A new opioid substrate for the polymorphic CYP2D6 in humans
53. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers
54. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics
55. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism
56. Comparative pharmacokinetic profiles of metoprolol and chlorthalidone administered alone or in combination to healthy volunteers
57. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity
58. Risk evaluation: Criteria arising from legal traditions and experience with quantitative risk assessment in the United States
59. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers
60. The metabolic fate of (2)H-labelled propafenone in man
61. Metoprolol in acute myocardial infarction. A pharmacokinetic and pharmacodynamic study
62. Pregnancy-induced increase in metoprolol metabolism
63. Investigations on the pharmacokinetics of propafenone in man
64. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man
65. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major C Upsilon P2D6 genotypes
66. The molecular genetics of the human drug metabolising cytochrome P450s
67. International Programme on Chemical Safety: Assessing human health risks of chemicals: Derivation of guidance values for health-based exposure limits
68. Intravenous and oral propafenone for treatment of tachycardia in infants and children: Pharmacokinetics and clinical response
69. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: Metoprolol, nadolol, and acebutolol
70. Variability of beta-blocker pharmacokinetics in young volunteers
71. Structural characterization of urinary metabolites of the antiarrhythmic drug encainide in human subjects
72. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine
73. Genetic analysis of the chinese cytochrome P4502D locus: Characterisation of variant CYP2D and genes present in subjects with diminished capacity for debrisoquine hydroxylation
74. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations
75. Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers
76. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite
77. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics
78. Stereoselective disposition and pharmacological activity of propafenone enantiomers
79. The effect of sertraline on the pharmacokinetics of desipramine and imipramine
80. Pharmacokinetic and pharmacodynamic interaction be mexiletine and propafenone in human beings
81. Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment
82. Identification of propafenone metaboliser phenotype from plasma and urine excretion data
83. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination
84. Acquisition of CYP2D6 and CYP3A activities in the first year of life
85. Influence of hepatic dysfunction on the pharmacokinetics of propafenone
86. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver
87. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine
88. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans
89. The effect of impaired renal function on the pharmacokinetics of metoprolol after single administration of a 14/190 metoprolol OROS system
90. The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers
91. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers
92. Polymorphic hydroxylation of debrisoquine in man
93. Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: Importance of enantioselective analytical methods
94. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes: The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase
95. Regioselectivity and enantioselectivity of metoprolol oxidation by two variants of cDNA-expressed P4502D6
96. Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants
97. E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation
98. Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients
99. Use of toxicokinetic and toxicodynamic data to reduce uncertainties when setting occupational exposure limits for pharmaceuticals
100. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes
101. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone
102. Venlafaxine oxidation in vitro is catalysed by CYP2D6
103. Pharmacokinetics of desipramine in Caucasian and Asian volunteers
104. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes
105. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6
106. Data-derived safety factors for the evaluation of food additives and environmental contaminants
107. Pathway-related defaults: The potential for human data to improve the scientific basis of risk assessment
108. Human variability and noncancer risk assessment - An analysis of the default uncertainty factor
109. Inter- and intra-subject variability of metoprolol kinetics after intravenous administration
110. Desipramine pharmacokinetics in Chinese and Caucasian volunteers
111. Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes
112. Pharmacokinetics of metoprolol enantiomers after administration of the racemate and the S-enantiomer as oral solutions and extended release tablets
113. Influence of debrisoquin phenotype on the inducibility of propranolol metabolism
114. Variation of pharmacokinetics after oral administration of slow-release metoprolol tablets and pharmacogenetic considerations
115. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences
116. Establishing data-derived uncertainty factors from published pharmaceutical clinical trial data
117. Influence of hydroxychloroquine on the bioavailability of oral metoprolol
118. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects
119. Phenobarbital induces the 2-hydroxylation of desipramine
120. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators
121. Pharmacokinetics of propafenone and its relationship with debrisoquin and mephenytoin metabolism polymorphisms in healthy Chinese volunteers
122. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam
123. The pharmacokinetics of venlafaxine when given in a twice daily regimen
124. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium
125. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine
126. The effect of renal disease on the disposition of venlafaxine
127. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol
128. Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers
129. Pharmacokinetics of once-daily venlafaxine extended release in healthy volunteers
130. The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine
131. The concept of the acceptable daily intake: An historical review
132. Polymorphic hydroxylation of debrisoquine
133. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man
134. Pharmacokinetics of venlafaxine in subjects with extensive and poor CYP2D6 activity
135. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine
136. Stereoselective hydroxylation of mexiletine in human liver microsomes: Implication of P450IID6 - A preliminary report
137. Nonlinear kinetics of propafenone metabolites in healthy man
138. Quantitative account of propranolol metabolism in urine of normal man
139. Categorical default factors for interspecies differences in the major routes of xenobiotic elimination
140. Uncertainty factors for chemical risk assessment: Interspecies differences in the pharmacokinetics of CYP1A2 probe substrates
141. Uncertainty factors for chemical risk assessment: Interspecies differences in the pharmacokinetics of glucuronidation
142. Influence of genetic polymorphism on the metabolism and disposition of encainide in man
143. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities
144. Pharmacokinetics of encainide in patients with cirrhosis
145. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias
146. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers - N-desisopropylation is mediated mainly by CYP1A2
147. Pharmacokinetics of codeine and its metabolites in caucasian healthy volunteers: Comparison between extensive and poor hydroxylators of debrisoquine
148. Pharmacokinetics and comparative bioavailability of two metoprolol tablet preparations
149. Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation